232 related articles for article (PubMed ID: 35636054)
21. Mutational spectrum of
Pettersson L; Holmgren B; Juliusson G; Lazarevic VL; Ehinger M
Leuk Lymphoma; 2021 Aug; 62(8):1958-1966. PubMed ID: 33711909
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
[TBL] [Abstract][Full Text] [Related]
24. [Effect of clonal hematopoiesis in remission on hematopoiesis recovery in patients with NPM1 mutated acute myeloid leukemia after chemotherapy].
Wang LL; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):845-850. PubMed ID: 38049337
[No Abstract] [Full Text] [Related]
25. Genetic biomarkers identify a subgroup of high-risk patients within low-risk
Carbonell D; Suárez-González J; Chicano M; Andrés-Zayas C; Díez-Díez M; Rodríguez-Macías G; Muñiz P; Kwon M; Anguita J; Díez-Martín JL; Buño I; Martínez-Laperche C
Leuk Lymphoma; 2021 May; 62(5):1178-1186. PubMed ID: 33372822
[TBL] [Abstract][Full Text] [Related]
26. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
27. Detection of NPM1 Mutations in Acute Myeloid Leukemia by using Drop-Off Droplet Digital PCR and its Clinical Application.
Jin Y; Xu ZJ; Yu D; Xia PH; Yao DM; Yuan Q; Li T; Xiang HL; Ma JC; Wen XM; Lin J; Qian J
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948486
[TBL] [Abstract][Full Text] [Related]
28. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
Jain P; Kantarjian H; Patel K; Faderl S; Garcia-Manero G; Benjamini O; Borthakur G; Pemmaraju N; Kadia T; Daver N; Nazha A; Luthra R; Pierce S; Cortes J; Ravandi F
Leuk Lymphoma; 2014 Jun; 55(6):1337-44. PubMed ID: 24004182
[TBL] [Abstract][Full Text] [Related]
29. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
30.
Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Patel K; Ganan-Gomez I; Jabbour E; Kadia T; Ravandi F; DiNardo C; Borthakur G; Takahashi K; Konopleva M; Komrokji RS; DeZern A; Kuzmanovic T; Maciejewski J; Pierce S; Colla S; Sekeres MA; Kantarjian H; Bueso-Ramos C; Garcia-Manero G
Blood Adv; 2019 Mar; 3(6):922-933. PubMed ID: 30902805
[TBL] [Abstract][Full Text] [Related]
31. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Montalban-Bravo G; Kanagal-Shamanna R; Class CA; Sasaki K; Ravandi F; Cortes JE; Daver N; Takahashi K; Short NJ; DiNardo CD; Jabbour E; Borthakur G; Naqvi K; Issa GC; Konopleva M; Khoury JD; Routbort M; Pierce S; Do KA; Bueso-Ramos C; Patel K; Kantarjian H; Garcia-Manero G; Kadia TM
Am J Hematol; 2020 Jun; 95(6):612-622. PubMed ID: 32112433
[TBL] [Abstract][Full Text] [Related]
33. TG-interacting factor 1 improves risk stratification in patients with NPM1-mutated acute myeloid leukemia.
Tang H; Zhang N; Li H; Chen Y; Liu X; Xiao H; Deng J; Zhou K
Adv Clin Exp Med; 2023 Jul; 32(7):741-751. PubMed ID: 36753372
[TBL] [Abstract][Full Text] [Related]
34. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
35. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.
Shouval R; Labopin M; Bomze D; Baerlocher GM; Capria S; Blaise D; Hänel M; Forcade E; Huynh A; Saccardi R; Milone G; Zuckerman T; Reményi P; Versluis J; Esteve J; Gorin NC; Mohty M; Nagler A
Bone Marrow Transplant; 2020 Dec; 55(12):2244-2253. PubMed ID: 32388535
[TBL] [Abstract][Full Text] [Related]
36. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
Daver N; Liu Dumlao T; Ravandi F; Pierce S; Borthakur G; Pemmaraju N; Nazha A; Faderl S; Jabbour E; Garcia-Manero G; Cortes J; Kantarjian H; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):435-40. PubMed ID: 23763915
[TBL] [Abstract][Full Text] [Related]
37. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.
Cocciardi S; Dolnik A; Kapp-Schwoerer S; Rücker FG; Lux S; Blätte TJ; Skambraks S; Krönke J; Heidel FH; Schnöder TM; Corbacioglu A; Gaidzik VI; Paschka P; Teleanu V; Göhring G; Thol F; Heuser M; Ganser A; Weber D; Sträng E; Kestler HA; Döhner H; Bullinger L; Döhner K
Nat Commun; 2019 May; 10(1):2031. PubMed ID: 31048683
[TBL] [Abstract][Full Text] [Related]
38. Overlapping features of therapy-related and de novo NPM1-mutated AML.
Othman J; Meggendorfer M; Tiacci E; Thiede C; Schlenk R; Dillon R; Stasik S; Venanzi A; Bertoli S; Delabesse E; Dumas PY; Pigneux A; Bidet A; Gilkes AF; Thomas I; Voso MT; Rambaldi A; Brunetti L; Perriello VM; Andresen V; Gjertsen BT; Martelli MP; Récher C; Röllig C; Bornhäuser M; Serve H; Müller-Tidow C; Baldus CD; Haferlach T; Russell N; Falini B
Blood; 2023 Apr; 141(15):1846-1857. PubMed ID: 36508705
[TBL] [Abstract][Full Text] [Related]
39. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
40.
Forghieri F; Nasillo V; Paolini A; Bettelli F; Pioli V; Giusti D; Gilioli A; Colasante C; Acquaviva G; Riva G; Barozzi P; Maffei R; Potenza L; Marasca R; Fozza C; Tagliafico E; Trenti T; Comoli P; Longo G; Luppi M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]